XENE earnings: next report 2026-08-10, real EPS beat/miss history, analyst consensus Buy, P/E -14.08. Updated 2026-07-23.
Xenon Pharmaceuticals (XENE) Research Hub
Xenon Pharmaceuticals (XENE) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 58.65 USD (-0.56%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -14.08, market cap 5.24B. This hub links to the full technical, earnings and options research available for XENE.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 58.65 USD (-0.56%) |
| 52-week range | 51.67 USD – 72.66 USD |
| Trend regime | Range |
| 14-day RSI | 33.5 (Bearish) |
| Trailing P/E | -14.08 |
| Market cap | 5.24B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for XENE
Covered Call on XENE: how it works, illustrative setup around the real 58.65 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on XENE: how it works, illustrative setup around the real 58.65 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on XENE: how it works, illustrative setup around the real 58.65 USD price, max profit/loss, breakeven and when to use it. Educational.
XENE technical analysis: range, last 58.65 USD, RSI 33.5, 52w range 51.67 USD–72.66 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is XENE in?
Xenon Pharmaceuticals (XENE) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is XENE in an uptrend or downtrend?
As of 2026-09-11, XENE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is XENE's trailing P/E ratio?
XENE's trailing P/E is -14.08, with a market cap of 5.24B. See the earnings research page for full valuation detail.
When does XENE next report earnings?
XENE is next scheduled to report earnings on 2026-08-10, with a consensus EPS estimate of -1.16 USD.